{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:33:07Z","timestamp":1781616787620,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270325"],"award-info":[{"award-number":["82270325"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-025-00342-5","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:58:20Z","timestamp":1747285100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and validation of an early prediction model for cardiac death risk in patients with light chain amyloidosis: a multicenter study"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6843-9867","authenticated-orcid":false,"given":"Naidong","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XingPeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"issue":"24","key":"342_CR1","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMra2304088","volume":"390","author":"V Sanchorawala","year":"2024","unstructured":"Sanchorawala V. Systemic light chain amyloidosis. N Engl J Med. 2024;390(24):2295\u2013307. https:\/\/doi.org\/10.1056\/NEJMra2304088.","journal-title":"N Engl J Med"},{"issue":"10","key":"342_CR2","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.3324\/haematol.2013.094482","volume":"98","author":"G Merlini","year":"2013","unstructured":"Merlini G, Palladini G. Light chain amyloidosis: the heart of the problem. Haematologica. 2013;98(10):1492\u20135. https:\/\/doi.org\/10.3324\/haematol.2013.094482.","journal-title":"Haematologica"},{"issue":"1","key":"342_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00392-019-01490-2","volume":"109","author":"F Escher","year":"2020","unstructured":"Escher F, Senoner M, Doerler J, et al. When and how do patients with cardiac amyloidosis die? Clin Res Cardiol. 2020;109(1):78\u201388. https:\/\/doi.org\/10.1007\/s00392-019-01490-2.","journal-title":"Clin Res Cardiol"},{"issue":"15","key":"342_CR4","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Gertz MA, Kumar SK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129(15):2111\u20139. https:\/\/doi.org\/10.1182\/blood-2016-11-751628.","journal-title":"Blood"},{"issue":"11","key":"342_CR5","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.jchf.2019.07.007","volume":"7","author":"CD Barrett","year":"2019","unstructured":"Barrett CD, Dobos K, Liedtke M, et al. A changing landscape of mortality for systemic light chain amyloidosis. JACC Heart Fail. 2019;7(11):958\u201366. https:\/\/doi.org\/10.1016\/j.jchf.2019.07.007.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"342_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000444206","volume":"2","author":"HL Nienhuis","year":"2016","unstructured":"Nienhuis HL, Bijzet J, Hazenberg BP. The prevalence and management of systemic amyloidosis in Western countries. Kidney Dis (Basel). 2016;2(1):10\u20139. https:\/\/doi.org\/10.1159\/000444206.","journal-title":"Kidney Dis (Basel)"},{"issue":"1","key":"342_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000444287","volume":"2","author":"XH Huang","year":"2016","unstructured":"Huang XH, Liu ZH. The clinical presentation and management of systemic Light-Chain amyloidosis in China. Kidney Dis (Basel). 2016;2(1):1\u20139. https:\/\/doi.org\/10.1159\/000444287.","journal-title":"Kidney Dis (Basel)"},{"issue":"18","key":"342_CR8","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","volume":"22","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751\u20137. https:\/\/doi.org\/10.1200\/JCO.2004.03.029.","journal-title":"J Clin Oncol"},{"issue":"9","key":"342_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989\u201395. https:\/\/doi.org\/10.1200\/JCO.2011.38.5724.","journal-title":"J Clin Oncol"},{"issue":"3","key":"342_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","volume":"133","author":"B Lilleness","year":"2019","unstructured":"Lilleness B, Ruberg FL, Mussinelli R, et al. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood. 2019;133(3):215\u201323. https:\/\/doi.org\/10.1182\/blood-2018-06-858951.","journal-title":"Blood"},{"issue":"9","key":"342_CR11","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.3390\/cancers16091689","volume":"16","author":"R R\u00edos-Tamayo","year":"2024","unstructured":"R\u00edos-Tamayo R, Lecumberri R, Cibeira MT, et al. A simple frailty score predicts survival and early mortality in systemic AL amyloidosis. Cancers (Basel). 2024;16(9):1689. https:\/\/doi.org\/10.3390\/cancers16091689.","journal-title":"Cancers (Basel)"},{"key":"342_CR12","doi-asserted-by":"publisher","unstructured":"Xing Y, Li X, Zhao J, et al. Advancing precision medicine in Immunoglobulin light-chain amyloidosis: a novel prognostic model incorporating multi-organ indicators. Intern Emerg Med. 2024 May;14. https:\/\/doi.org\/10.1007\/s11739-024-03621-8.","DOI":"10.1007\/s11739-024-03621-8"},{"issue":"15","key":"342_CR13","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","volume":"124","author":"G Palladini","year":"2014","unstructured":"Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325\u201332. https:\/\/doi.org\/10.1182\/blood-2014-04-570010.","journal-title":"Blood"},{"issue":"5","key":"342_CR14","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.3324\/haematol.2023.284348","volume":"109","author":"J Khwaja","year":"2024","unstructured":"Khwaja J, Ravichandran S, Bomsztyk J, et al. Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients. Haematologica. 2024;109(5):1598\u2013602. https:\/\/doi.org\/10.3324\/haematol.2023.284348.","journal-title":"Haematologica"},{"issue":"4","key":"342_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jaccao.2022.08.009","volume":"4","author":"AD Wechalekar","year":"2022","unstructured":"Wechalekar AD, Fontana M, Quarta CC, et al. AL amyloidosis for cardiologists: awareness, diagnosis, and future prospects: JACC: cardiooncology State-of-the-Art review. JACC CardioOncol. 2022;4(4):427\u201341. https:\/\/doi.org\/10.1016\/j.jaccao.2022.08.009.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"342_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2023.12.006","volume":"6","author":"L De Michieli","year":"2024","unstructured":"De Michieli L, Cipriani A, Iliceto S, et al. Cardiac troponin in patients with light chain and transthyretin cardiac amyloidosis: JACC: cardiooncology State-of-the-Art review. JACC CardioOncol. 2024;6(1):1\u201315. https:\/\/doi.org\/10.1016\/j.jaccao.2023.12.006.","journal-title":"JACC CardioOncol"},{"issue":"11","key":"342_CR17","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"C Writing","year":"2023","unstructured":"Writing C, Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: A report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2023;81(11):1076\u2013126. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.022.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"342_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/CM9.0000000000002961","volume":"137","author":"K Shen","year":"2024","unstructured":"Shen K, Tian Z, Gao Y, et al. Chinese consensus on the diagnosis and treatment of Immunoglobulin light-chain cardiac amyloidosis. Chin Med J (Engl). 2024;137(2):127\u20139. https:\/\/doi.org\/10.1097\/CM9.0000000000002961.","journal-title":"Chin Med J (Engl)"},{"issue":"8","key":"342_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","volume":"11","author":"A Staron","year":"2021","unstructured":"Staron A, Zheng L, Doros G, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021;11(8):139. https:\/\/doi.org\/10.1038\/s41408-021-00529-w.","journal-title":"Blood Cancer J"},{"issue":"2","key":"342_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/13506129.2021.2013193","volume":"29","author":"M Kharoubi","year":"2022","unstructured":"Kharoubi M, Bodez D, B\u00e9zard M, et al. Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival. Amyloid. 2022;29(2):79\u201391. https:\/\/doi.org\/10.1080\/13506129.2021.2013193.","journal-title":"Amyloid"},{"key":"342_CR21","doi-asserted-by":"publisher","first-page":"817456","DOI":"10.3389\/fcvm.2022.817456","volume":"9","author":"Y Wu","year":"2022","unstructured":"Wu Y, Pu C, Zhu W, et al. A risk score to diagnose cardiac involvement and provide prognosis information in patients at risk of cardiac Light-Chain amyloidosis. Front Cardiovasc Med. 2022;9:817456. https:\/\/doi.org\/10.3389\/fcvm.2022.817456.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"342_CR22","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","volume":"126","author":"G Palladini","year":"2015","unstructured":"Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612\u20135. https:\/\/doi.org\/10.1182\/blood-2015-01-620302.","journal-title":"Blood"},{"issue":"6","key":"342_CR23","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","volume":"28","author":"E Kastritis","year":"2010","unstructured":"Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031\u20137. https:\/\/doi.org\/10.1200\/JCO.2009.23.8220.","journal-title":"J Clin Oncol"},{"issue":"19","key":"342_CR24","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","volume":"119","author":"CP Venner","year":"2012","unstructured":"Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387\u201390. https:\/\/doi.org\/10.1182\/blood-2011-10-388462.","journal-title":"Blood"},{"issue":"1","key":"342_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-Based treatment for Immunoglobulin Light-Chain amyloidosis. N Engl J Med. 2021;385(1):46\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2028631.","journal-title":"N Engl J Med"},{"issue":"18","key":"342_CR26","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1182\/blood.2019004436","volume":"135","author":"V Sanchorawala","year":"2020","unstructured":"Sanchorawala V, Sarosiek S, Schulman A, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood. 2020;135(18):1541\u20137. https:\/\/doi.org\/10.1182\/blood.2019004436.","journal-title":"Blood"},{"issue":"18","key":"342_CR27","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1182\/blood.2019004369","volume":"135","author":"M Roussel","year":"2020","unstructured":"Roussel M, Merlini G, Chevret S, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light chain amyloidosis. Blood. 2020;135(18):1531\u201340. https:\/\/doi.org\/10.1182\/blood.2019004369.","journal-title":"Blood"},{"issue":"5","key":"342_CR28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/hon.267","volume":"37","author":"R Schwotzer","year":"2019","unstructured":"Schwotzer R, Manz MG, Pederiva S, et al. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden. Hematol Oncol. 2019;37(5):595\u2013600. https:\/\/doi.org\/10.1002\/hon.267.","journal-title":"Hematol Oncol"},{"issue":"3","key":"342_CR29","doi-asserted-by":"publisher","first-page":"euae063","DOI":"10.1093\/europace\/euae063","volume":"26","author":"Z Chen","year":"2024","unstructured":"Chen Z, Shi A, Dong H, et al. Prognostic implications of premature ventricular contractions and non-sustained ventricular tachycardia in light-chain cardiac amyloidosis. Europace. 2024;26(3):euae063. https:\/\/doi.org\/10.1093\/europace\/euae063.","journal-title":"Europace"},{"issue":"5","key":"342_CR30","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/his.12793","volume":"68","author":"BT Larsen","year":"2016","unstructured":"Larsen BT, Mereuta OM, Dasari S, et al. Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases. Histopathology. 2016;68(5):648\u201356. https:\/\/doi.org\/10.1111\/his.12793.","journal-title":"Histopathology"},{"issue":"4","key":"342_CR31","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jchf.2014.03.009","volume":"2","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, Vangala D, Bruyere J Jr, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014;2(4):358\u201367. https:\/\/doi.org\/10.1016\/j.jchf.2014.03.009.","journal-title":"JACC Heart Fail"},{"issue":"6","key":"342_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa325","volume":"4","author":"HT Nguyen","year":"2020","unstructured":"Nguyen HT, Nguyen CTH. Cardiac amyloidosis mimicking acute coronary syndrome: a case report and literature review. Eur Heart J Case Rep. 2020;4(6):1\u20137. https:\/\/doi.org\/10.1093\/ehjcr\/ytaa325.","journal-title":"Eur Heart J Case Rep"},{"issue":"3","key":"342_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3109\/13506129.2011.571319","volume":"18","author":"SB Tsai","year":"2011","unstructured":"Tsai SB, Seldin DC, Wu H, et al. Myocardial infarction with clean coronaries caused by amyloid light-chain AL amyloidosis: a case report and literature review. Amyloid. 2011;18(3):160\u20134. https:\/\/doi.org\/10.3109\/13506129.2011.571319.","journal-title":"Amyloid"},{"issue":"10","key":"342_CR34","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1002\/ejhf.2276","volume":"23","author":"M Pagnesi","year":"2021","unstructured":"Pagnesi M, Adamo M, Sama IE, et al. Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF. Eur J Heart Fail. 2021;23(10):1750\u20138. https:\/\/doi.org\/10.1002\/ejhf.2276.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"342_CR35","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ejhf.2858","volume":"25","author":"G Heitzinger","year":"2023","unstructured":"Heitzinger G, Pavo N, Koschatko S, et al. Contemporary insights into the epidemiology, impact and treatment of secondary tricuspid regurgitation across the heart failure spectrum. Eur J Heart Fail. 2023;25(6):857\u201367. https:\/\/doi.org\/10.1002\/ejhf.2858.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"342_CR36","doi-asserted-by":"publisher","first-page":"102417","DOI":"10.1016\/j.cpcardiol.2024.102417","volume":"49","author":"I Minga","year":"2024","unstructured":"Minga I, Kwak E, Hussain K, et al. Prevalence of valvular heart disease in cardiac amyloidosis and impact on survival. Curr Probl Cardiol. 2024;49(4):102417. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102417.","journal-title":"Curr Probl Cardiol"},{"issue":"7","key":"342_CR37","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/ehjci\/jeae060","volume":"25","author":"D Tomasoni","year":"2024","unstructured":"Tomasoni D, Aimo A, Porcari A, et al. Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2024;25(7):1007\u201317. https:\/\/doi.org\/10.1093\/ehjci\/jeae060.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"26","key":"342_CR38","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol. 2015;33(26):2863\u20139. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267.","journal-title":"J Clin Oncol"},{"issue":"21","key":"342_CR39","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1182\/blood.2019003807","volume":"135","author":"V Royal","year":"2020","unstructured":"Royal V, Leung N, Troyanov S, et al. Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. Blood. 2020;135(21):1833\u201346. https:\/\/doi.org\/10.1182\/blood.2019003807.","journal-title":"Blood"},{"key":"342_CR40","doi-asserted-by":"publisher","first-page":"1322680","DOI":"10.3389\/fonc.2024.1322680","volume":"14","author":"T Zhang","year":"2024","unstructured":"Zhang T, Lin Z, Zheng Z, et al. Prognostic significance of \u03b22-microglobulin decline index in multiple myeloma. Front Oncol. 2024;14:1322680. https:\/\/doi.org\/10.3389\/fonc.2024.1322680.","journal-title":"Front Oncol"},{"issue":"1","key":"342_CR41","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1053\/j.ajkd.2016.01.015","volume":"68","author":"MC Foster","year":"2016","unstructured":"Foster MC, Coresh J, Hsu CY, et al. Serum \u03b2-Trace protein and \u03b22-Microglobulin as predictors of ESRD, mortality, and cardiovascular disease in adults with CKD in the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2016;68(1):68\u201376. https:\/\/doi.org\/10.1053\/j.ajkd.2016.01.015.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"342_CR42","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1053\/j.ajkd.2011.11.042","volume":"59","author":"BC Astor","year":"2012","unstructured":"Astor BC, Shafi T, Hoogeveen RC, et al. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am J Kidney Dis. 2012;59(5):653\u201362. https:\/\/doi.org\/10.1053\/j.ajkd.2011.11.042.","journal-title":"Am J Kidney Dis"},{"issue":"24","key":"342_CR43","doi-asserted-by":"publisher","first-page":"11955","DOI":"10.18632\/aging.102520","volume":"11","author":"ZT Hilt","year":"2019","unstructured":"Hilt ZT, Ture SK, Mohan A, et al. Platelet-derived \u03b22m regulates age related monocyte\/macrophage functions. Aging. 2019;11(24):11955\u201374. https:\/\/doi.org\/10.18632\/aging.102520.","journal-title":"Aging"},{"issue":"16","key":"342_CR44","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1042\/CS20180486","volume":"132","author":"Y Li","year":"2018","unstructured":"Li Y, Zhang X, Li L, et al. Mechanical stresses induce paracrine \u03b2-2 microglobulin from cardiomyocytes to activate cardiac fibroblasts through epidermal growth factor receptor. Clin Sci (Lond). 2018;132(16):1855\u201374. https:\/\/doi.org\/10.1042\/CS20180486.","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"342_CR45","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/ejhf.2769","volume":"25","author":"G Vergaro","year":"2023","unstructured":"Vergaro G, Castiglione V, Aimo A, et al. N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis. Eur J Heart Fail. 2023;25(3):335\u201346. https:\/\/doi.org\/10.1002\/ejhf.2769.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"342_CR46","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1200\/JCO.22.00643","volume":"41","author":"E Muchtar","year":"2023","unstructured":"Muchtar E, Dispenzieri A, Wisniowski B, et al. Graded cardiac response criteria for patients with systemic light chain amyloidosis. J Clin Oncol. 2023;41(7):1393\u2013403. https:\/\/doi.org\/10.1200\/JCO.22.00643.","journal-title":"J Clin Oncol"},{"issue":"5","key":"342_CR47","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/ehjci\/jead351","volume":"25","author":"A Briasoulis","year":"2024","unstructured":"Briasoulis A, Bampatsias D, Petropoulos I, et al. Left ventricular myocardial work improves in response to treatment and is associated with survival among patients with light chain cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2024;25(5):698\u2013707. https:\/\/doi.org\/10.1093\/ehjci\/jead351.","journal-title":"Eur Heart J Cardiovasc Imaging"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00342-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-025-00342-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00342-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:58:21Z","timestamp":1747285101000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-025-00342-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["342"],"URL":"https:\/\/doi.org\/10.1186\/s40959-025-00342-5","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"12 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}